Robert Plenge, M.D., Ph.D., joined BioMarin’s Board of Directors in September 2026. He currently serves as Executive Vice President and Chief Research Officer at Bristol Myers Squibb, where he leads scientific activities across nine research sites around the world.

Dr. Plenge joined BMS as part of the Celgene acquisition in November 2019. At Celgene, he served as Vice President, Immunology & Inflammation Portfolio, Research & Early Development. Prior to joining Celgene, Dr. Plenge was Vice President and Head of Translational Medicine at Merck. Earlier in his career, he served as an assistant professor of medicine at Harvard Medical School and an associate member of the Broad Institute.

Dr. Plenge received his M.D. and Ph.D. from Case Western Reserve University and holds a bachelor’s degree from the University of California, San Diego. He completed his internal medicine residency as a molecular medicine fellow at the University of California, San Francisco. He served as rheumatology fellow at Brigham & Women’s Hospital and postdoctoral research fellow at the Broad Institute of MIT and Harvard.

He currently serves on the boards of directors for Alltrna and the PhRMA Foundation.